Robert Noone, MD
Colon & Rectal Surgery · Wynnewood, PANPI 1881697845
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (45.4%), education and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 72.7% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2019 at $2,127 and has fallen 86.3% since, to $292 in 2025.
Across 40 payments — averaging $77.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$2K
- Conmed Corporation$254
- Teleflex LLC$115
- Medtronic$74
- Novartis$56
- Johnson & Johnson$55
- plus $290 from 13 others
What the payments were for
- Travel & lodging$68722%
- Food & beverage$1,40345%
- Education$1,00032%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 15 | $2,246 |
| Conmed Corporation | 2 | $254 |
| Teleflex LLC | 1 | $115 |
| Medtronic | 3 | $74 |
| Novartis | 2 | $56 |
| Johnson & Johnson | 2 | $55 |
| Pfizer | 3 | $43 |
| Caris MPI, Inc. | 1 | $33 |
| Davol Inc. | 1 | $24 |
| Abbott | 1 | $22 |
| Innocoll Pharmaceuticals Limited | 1 | $22 |
| Incyte Corporation | 1 | $21 |
| Edwards Lifesciences | 1 | $20 |
| KCI USA, Inc. | 1 | $20 |
| AstraZeneca | 1 | $18 |
| Axonics, Inc. | 1 | $18 |
| Covidien LP | 1 | $18 |
| Bayer | 1 | $18 |
| Mission Pharmacal Company | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$2,009
- AIRSEAL$175
- Solesta$115
How this compares
$3,090 in reported general payments places this provider in the 55th percentile of 108 colon & rectal surgery providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin Sulfate | 12 | $62 |
| Metronidazole | 15 | $37 |
Paid to pharmacies, not to this prescriber.
Other colon & rectal surgery in Wynnewood
- John MarksWynnewood$155K
- Henry SchoonyoungWynnewood$11K
- Bogdan ProtyniakWilkes-Barre$429K
- Joshua BleierPhiladelphia$86K
- Richard FortunatoPittsburgh$80K
- Najjia MahmoudPhiladelphia$63K
- James McCormickMonroeville$55K
- Juan PoggioPhiladelphia$49K
- Christopher BuzasDanville$25K
- David ZebleyAbington$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.